TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations-Reference-Cited by-同舟云学术

TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations

Published:2024-06-25 Issue:31 Volume:43 Page:2421-2430
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Ghezelayagh Talayeh S.,Kohrn Brendan F.,Fredrickson Jeanne,Krimmel-Morrison Jeffrey D.,Latorre-Esteves Elena,Tee Xin-Ray,Radke Marc R.,Manhardt Enna,Norquist Barbara M.,Katz Ronit,Swisher Elizabeth M.,Risques Rosa Ana^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41388-024-03089-y.pdf

Reference48 articles.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.

2. Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, et al. TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. Int J Gynecol Cancer. 2019;29:346–52.

3. Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 2019;28:3010.

4. Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, et al. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. Gynecol Oncol. 2021;160:786–92.

5. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105:812–22.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations;Gynecologic Oncology;2024-11